Patients with locally advanced (stage IIIB or IIIC) or metastatic (stage IV) NSCLC and had not previously undergone curative surgery or chemoradiation; confirmed EGFR (Ex19del and/or 21 L858R) mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.